English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dear Editor, After the licensing of dolutegravir, a debate has begun to assess its tolerability beyond the pivotal trials’ data comparing it with the tolerability profiles of the other integrase inhibitors on the market, with conflicting evidence [1, 2]. Boosted and unboosted atazanavir increase dolutegravir plasma concentrations by 1.5to 2-fold [3]. In this study, we wanted to analyze whether a combination that yields high concentrations of dolutegravir may also cause more frequent or more severe adverse events. This study is part of a comprehensive retrospective–prospective analysis of all subjects who have taken dolutegravir (even once in their life). The current analysis was performed on the population followed by the outpatient clinic of the 1st Division of Infectious Diseases of Luigi Sacco Hospital, Milan, and by that of the Institute of Clinical Infectious Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS– Catholic University of the Sacred Heart, Rome. Ethics committee approval has been obtained and informed consent signed within the larger “Odoacre” Observational Cohort to which the study subgroups pertain. No further conditions were required to be eligible for the analysis. For this particular analysis only, dual therapies with dolutegravir were selected. All subjects taking dolutegravir-based dual therapies for more than 1 day from January 2014 to June 2017 were retrospectively reviewed and prospectively assessed. Demographic data, treatment history, and virologic, immunologic, and clinical outcomes including adverse events were recorded at the time of the visits. In the case of adverse events, further questions were posed to the physicians. Adverse events and neurological adverse events were classified according to the the Common Terminology Criteria for Adverse Events (version 4.03) [4]. Five hundred seventy-three patients (10% of the HIV-infected outpatient population) were taking dolutegravir-based dual therapies. Dolutegravir and its companion drug plasma Cmin have been evaluated in 46 subjects on atazanavir (ATV; median [range], 2822 [187–6432] ng/mL), 35 on boosted darunavir (median [range], 1026 [191–4978] ng/mL), 31 on rilpivirine (median [range], 798 [194–3941] ng/mL), and 27 on lamivudine (median [range], 893 [198–2651] ng/mL), confirming the boosting effect of ATV. The incidence rates of neurological adverse events and of discontinuations due to neurological adverse events are reported in Table 1. The overall incidence of neurological adverse events was very low (2.39%), and the incidence of those leading to discontinuation was only 1.95%, whereas the incidence of sleep disorders was 0.71%, as most patients were taking antiretrovirals applyparastyle “fig//caption/p[1]” parastyle “FigCapt”

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?